INDOCO vs STAR: Stock Comparison

INDOCO REMEDIES vs STRIDES PHARMA SCIUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

STRIDES PHARMA SCI is the larger company by market capitalisation. INDOCO REMEDIES shows faster revenue growth, while STRIDES PHARMA SCI shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

INDOCO leads 2; STAR leads 11 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

INDOCOSTAR

Valuation lens

What price are you paying?

Market CapContext only
₹2,421 Cr
₹9,754 Cr
P/E RatioSTAR has the lower reading
445.9x
15.76x
P/B RatioINDOCO has the lower reading
2.67x
3.11x
EPSSTAR has the higher reading
₹7.04
₹17.02
Book ValueContext only
₹100.98
₹341.68
Dividend YieldSTAR has the higher reading
0%
0.49%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
STAR is the larger company
₹9,754 Cr vs ₹2,421 Cr
P/E Ratio
STAR has a lower P/E
15.76x vs 445.9x
P/B Ratio
INDOCO has a lower P/B
2.67x vs 3.11x
EPS
STAR has higher earnings per share
₹17.02 vs ₹7.04
Dividend Yield
STAR has a higher dividend yield
0.49% vs 0%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs 11.2%
EPS Growth (TTM YoY)
STAR has faster EPS growth
54.4% vs 0%
Qtr Sales Growth
STAR has stronger quarterly sales growth
117.18% vs 14.31%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOSTAR
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOSTAR
Live Price₹262.51₹1,059.6
Day Change-3.69%0.57%
Volume3.69 L2.17 L
52-Week High₹332.2₹1,231
52-Week Low₹162.19₹768.65
Distance from 52W High-20.98%-13.92%

Valuation

MetricINDOCOSTAR
Market Cap₹2,421 Cr₹9,754 Cr
P/E Ratio445.9x15.76x
P/B Ratio2.67x3.11x
EPS₹7.04₹17.02
Book Value₹100.98₹341.68
Dividend Yield0%0.49%

Growth

MetricINDOCOSTAR
Revenue Growth (TTM YoY)21.9%11.2%
EPS Growth (TTM YoY)0%54.4%
Qtr Sales Growth14.31%117.18%
Qtr Profit Growth-20.51%126.93%

Profitability & Leverage

MetricINDOCOSTAR
ROE-0.51%5.59%
ROCE4.26%4.43%
Net Margin-5.31%10.58%
Operating Margin4.57%14.53%
Debt to Equity0.64x0.35x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOSTAR
Promoter Holding58.86%27.91%
FII Holding1.27% 0.33 pp28.39% 0.29 pp
DII Holding17.68% 0.47 pp15.41% 0.96 pp
Public Holding22.04% 0.14 pp28.28% 0.67 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDOCO REMEDIES and STRIDES PHARMA SCI.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.